Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.939 USD | +2.44% | +2.19% | -33.57% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.57% | 139M | |
+9.85% | 118B | |
+10.14% | 106B | |
-11.64% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.51% | 15.97B | |
+6.39% | 14.03B | |
+16.23% | 11.67B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Oppenheimer Trims Seres Therapeutics Price Target to $9 From $10, Maintains Outperform Rating